Evidence map›Paper›PMID 36940787›Full record

ArticleThe journal of pain2023

The Association Between Immune-Related Conditions Across the Life-Course and Provoked Vulvodynia.

Bernard L Harlow, Chad M Coleman, Hanna Mühlrad, Jacinth Yan, Evelina Linnros, Donghao Lu, Matthew P Fox, Nina Bohm-Starke

Abstract read
In one paragraph

Article in The journal of pain, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Immune mechanisms in vulvodynia: key roles for mast cells and fibroblasts.Frontiers in cellular and infection microbiology · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bernard L HarlowDepartment of Epidemiology, Boston University School of Public Health. Boston, Massachusetts. Electronic address: harlow@bu.edu.
Chad M ColemanDepartment of Epidemiology, Boston University School of Public Health. Boston, Massachusetts.
Hanna MühlradDepartment of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden; The Institute for Evaluation of Labor Market and Education Policy (IFAU), Uppsala, Sweden.
Jacinth YanInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Evelina LinnrosInstitute for International Economic Studies, Stockholm University, Stockholm, Sweden.
Donghao LuInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Matthew P FoxDepartment of Epidemiology, Boston University School of Public Health. Boston, Massachusetts; Department of Global Health, Boston University School of Public Health, Boston, Massachusetts.
Nina Bohm-StarkeDepartment of Clinical Sciences, Division of Obstetrics and Gynecology, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden.

Funding

Risk of vulvodynia due to immune-related health events throughout the life courseR21HD099533 · NICHD · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HARLOW, BERNARD L · 2020 to 2021
$399k
NICHD NIH HHS R21 HD099533
6 · The paper itself

Abstract

Vulvodynia, impacts up to 8% of women by age 40, and is hypothesized to manifest through an altered immune-inflammatory response. To test this hypothesis, we identified all women born in Sweden between 1973 and 1996 diagnosed with localized provoked vulvodynia (N76.3) and/or vaginismus (N94.2 or F52.5) between 2001 and 2018. We matched each case to two women from the same birth year with no vulvar pain ICD codes. As a proxy for immune dysfunction, we used Swedish Registry data to capture 1) immunodeficiencies, 2) single organ and multiorgan autoimmune conditions, 3) allergy and atopies, and 4) malignancies involving immune cells across the life course. Women with vulvodynia, vaginismus or both were more likely to experience immune deficiencies (OR 1.8, 95% CI, 1.2-2.8), single organ (OR 1.4, 95% CI, 1.2-1.6) and/or multi-organ (OR 1.6, 95% CI, 1.3-1.9) immune disorders, and allergy/atopy conditions (OR 1.7, 95% CI, 1.6-1.8) compared to controls. We observed greater risk with increasing numbers of unique immune related conditions (1 code: OR = 1.6, 95% CI, 1.5-1.7; 2 codes: OR = 2.4, 95% CI, 2.1-2.9; 3 or more codes: OR = 2.9, 1.6-5.4). These findings suggest that women with vulvodynia may have a more compromised immune system either at birth or at points across the life course than women with no vulvar pain history. PERSPECTIVE: Women with vulvodynia are substantially more likely to experience a spectrum of immune related conditions across the life course. These findings lend support to the hypothesis that chronic inflammation initiates the hyperinnervation that causes the debilitating pain in women with vulvodynia.

Indexed as

DyspareuniaHypersensitivityVaginismusVulvodyniaAdultFemaleHumansInfant, NewbornLife Change EventsPainimmune dysfunctioninflammationlife courserisk factorsVulvodynia

Identifiers

PMID36940787
PMCPMC10440273

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.